NR1H4 and primary biliary cholangitis: Obeticholic acid (6-ethyl-CDCA) (OCA) is a potent FXR agonist approved by FDA for the treatment of primary biliary cholangitis and recently successfully passed a phase 3 trial for fibrosis due to NASH.